This first in a series of reports on liquid biopsies looks at biomarker classes linked to that research space.!--h2>
Enal Razvi, Ph.D.
Gary Oosta, Ph.D.
The focus of this GEN Market & Tech Analysis report is to present some of our most recent analysis of publication trends across a number of biomarker classes with an eye toward categorizing them into segments especially as they relate to liquid biopsies.
This is the first report in a series of several to be published by GEN over the coming months focusing on the emerging and rapidly evolving field of liquid biopsies.
Focused herein are the various classes of circulating biomarkers, which provide the starting material for the development of liquid biopsies.
We’ve focused on circulating tumor cells (CTCs), circulating DNA, circulating RNA, and exosomes for the analysis presented herein.
These four analyte classes represent the current state of the art vis-à-vis circulating biomarkers, and there is much debate as to which marker[s] will provide prognostic and predictive utility across a wide swath of disease classes in the future—hence the vigorous research interest in all these spaces.
Enal Razvi, Ph.D., conducted his doctoral work on viral immunology and subsequent to receiving his Ph.D. went on to the Rockefeller University in New York to serve as Aaron Diamond Post-doctoral fellow under Professor Ralph Steinman [Nobel Prize Winner in 2011 for his discovery of dendritic cells in the early-70s with Zanvil Cohn]. Subsequently, Dr. Razvi completed his research fellowship at Harvard Medical School. For the last two decades Dr. Razvi has worked with small and large companies and consulted for more than 100 clients worldwide. He currently serves as Biotechnology Analyst and Managing Director of SelectBio U.S. He can be reached at firstname.lastname@example.org.
Gary M. Oosta holds a Ph.D. in Biophysics from Massachusetts Institute of Technology and a B.A. in Chemistry from E. Mich. Univ. He has 25 years of industrial research experience in various technology areas including medical diagnostics, thin-layer coating, bio-effects of electromagnetic radiation, and blood coagulation. Dr. Oosta has authored 20 technical publications and is an inventor on 77 patents worldwide. In addition, he has managed research groups that were responsible for many other patented innovations. Dr. Oosta has a long-standing interest in using patents and publications as strategic technology indicators for future technology selection and new product development.